l General Information |
Product Name | Rimonabant |
General description | Rimonabant is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. |
Synonym | 5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide; SR-141716; SR-141716A; |
Purity | ≥99%(HPLC) | CAS Number | 168273-06-1 |
Formula | C22H21Cl3N4O | Molecular Weight | 463.787 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | White or Off-white solid |
Solubility(25℃) | DMSO | ≥20mg/mL |
Ethanol | ~2mg/mL |
Water | insoluble |
l Biological Information |
Biochem/Physiol Actions | In the RIO-North America trial, 3040 patients were randomized to receive either placebo or one of two doses of rimonabant (5 mg or 20 mg per day). Patients taking 20 mg rimonabant had significant weigh loss, decrease in waist circumference, improved insulin sensitivity, and increases in HDL cholesterol, compared to patients on placebo. |
Application | Cannabinoid Receptor Antagonists Compounds that inhibit or block the activity of CANNABINOID RECEPTORS. |
l Packaging & Storage |
Packaging | 50mg; 250mg; |
Storage temp. | 0-5℃ |
l Precautions and Disclaimer |
This product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
